Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Company Limited American Depositary Shares (each
(NY:
TAK
)
17.86
+0.09 (+0.53%)
Streaming Delayed Price
Updated: 3:50 PM EST, Mar 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
March 03, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
January 30, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Preview: Takeda Pharmaceutical's Earnings
↗
October 30, 2024
Via
Benzinga
Earnings Scheduled For January 30, 2025
↗
January 30, 2025
Via
Benzinga
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
January 30, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
↗
January 28, 2025
Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.
Via
Benzinga
FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch
↗
January 15, 2025
The U.S. Food and Drug Administration announced a ban on Red No. 3, an artificial food coloring linked to cancer in animal studies, effective Jan. 15, 2027.
Via
Benzinga
Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency
↗
December 27, 2024
Takeda's HYQVIA receives approval in Japan for treating immunodeficiencies, offering a more convenient, less frequent subcutaneous infusion option.
Via
Benzinga
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
December 27, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
↗
December 18, 2024
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets.
Via
Benzinga
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
December 12, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
December 12, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
↗
December 03, 2024
Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in myelodysplastic syndromes.
Via
Benzinga
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
December 03, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
November 21, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
↗
November 14, 2024
AC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease.
Via
Benzinga
Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump
↗
November 12, 2024
Global leaders gather at COP29 to address climate change, carbon market mechanisms, and climate finance. Urgency and controversy at a fossil fuel reliant host country, but focus on establishing rules...
Via
Benzinga
Topics
Climate Change
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
October 31, 2024
— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer —
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
October 31, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
October 24, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
↗
October 17, 2024
HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers...
Via
Benzinga
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
↗
October 04, 2024
Johnson & Johnson has discontinued its Phase 2 study of mosnodenvir, an investigational antiviral candidate for dengue prevention, as part of a strategic shift in its R&D portfolio. Final efficacy data...
Via
Benzinga
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
September 24, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
September 24, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
September 20, 2024
Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment.
Via
MarketBeat
Topics
Economy
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
September 19, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
September 18, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
↗
September 10, 2024
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential.
Via
Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
↗
September 09, 2024
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...
Via
Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
↗
September 06, 2024
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
